Targets › LTBR
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
Receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. Activates NF-kappa-B signaling pathway upon stimulation with lymphotoxin (LTA(1)-LTB(2)). Promotes apoptosis via TRAF3 and TRAF5. (UniProt, P36941)
Open in Phaseline: the race on LTBR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mestag Therapeutics | MST-0312 Bispecific antibody targeting lymphotoxin beta receptor (LTBR) | LTBR | Phase 1 | Cancer-Neoplasms | Dec 2029 |
Cancer-Neoplasms (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.